Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIPIT: Combination Therapy in New-Onset Type 1 Diabetes
NCT02586831Phase 2Withdrawn
- Start
- Jun 2024
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Cytokines & Interferons, Peptides
01
Overview
A Phase 2 trial of antithymocyte globulin, aldesleukin, adalimumab, exenatide in type 1 diabetes mellitus (T1D). Planned start Jun 2024; status: withdrawn.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02586831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02586831.